Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New wound dressing aims to speed healing and fight infection

NCT ID NCT07576322

First seen May 13, 2026 · Last updated Jun 23, 2026 · Updated 6 times

Summary

This study compares a new dressing called POLTX_Fiber to a standard one (Suprasorb Liquacel Pro) for chronic wounds like leg ulcers and pressure sores. About 60 adults with moderate-to-heavy wound drainage will be followed for 30 days. Researchers will track wound healing, infection signs, pain, and patient satisfaction using photos and assessments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WOUND CARE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Geneva University Hospitals

    Geneva, Canton of Geneva, 1205, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituions Hospital Du Nord Vaudois

    Yverdon-les-Bains, Canton of Vaud, 1400, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lausanne University Hospital

    Lausanne, Canton of Vaud, 1002, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

POLTX_Fiber dressing

What this could lead to

If it works, this could provide a better option for managing chronic wounds, potentially improving healing and reducing infection risk.

What could go wrong

This is a small, early-stage study with only 60 participants, so results may not apply to everyone. The dressing is already approved, so major risks are low, but it may not outperform the standard dressing.

Conditions

The condition(s) this trial relates to.

infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.